MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today issued its year-end shareholder letter. In the update, the company’s CEO and Founder Patrick Bertagna shared insight on the company’s restructuring, branding and efforts to attract new investors and larger customers to execute its growth strategy, as well as the milestones that will shape MetAlert’s future. “We are now taking dramatic steps to align the public-facing (stock) part of the company with the operations and vision of the company. Although the short-term performance of the stock has not been what we anticipated, we are confident in the actions taken and that we are on the right path,” Bertagna said in the letter. “As we continue to lead the company forward, exciting opportunities await. Strategic acquisitions, expanding our products and services, and increasing our revenues per user (‘RPU’) should help set us on a path toward continued success in the coming months and years. Moreover, aligning with new technologies could open possibilities for crucial data analysis that has the potential to revolutionize how we conduct and manage health care worldwide. Our vision is for this trajectory to take us beyond traditional bounds into an even brighter future, where we see our organization standing strong amongst multibillion-dollar corporations. With these ambitious plans, we invite all shareholders to connect with us as we hit the ground running in this new year.”
To view the full press release, visit https://ibn.fm/IMdXU
About MetAlert Inc.
MetAlert is a pioneer in smart, mobile and wearable tracking and recovery location-based solutions, supported through a proprietary IOT enterprise monitoring platform and intellectual property portfolio. The company offers global end-to-end solutions of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications, utilizing the latest in miniaturized, low power consumption GPS, cellular, RF, NFC, and BLE technology, enabling subscribers to track in real time the whereabouts of people or high value assets. MetAlert is known for its game-changing and award-winning patented GPS SmartSole – think Dr. Scholl’s meets LoJack, the world’s first visible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism and traumatic brain injury. MetAlert’s business model is built around technology innovation and the company holds dozens of patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing customers across the globe with subscribers in over 40 countries and is a U.S. military government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. For more information, visit the company’s website at www.MetAlert.com.
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
